Scoop has an Ethical Paywall
Munchkin US FDA Process on hold
SYNLAIT MILK LIMITED ANNOUNCEMENT NZX: SML
ASX: SM1
16 May 2019
MUNCHKIN U.S. FDA PROCESS ON HOLD
The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin’s Grass Fed™ infant formula in the U.S. has been put on hold.
Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow Munchkin to explore other options in the U.S.
“Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed™ is sold the relationship continues with business as usual,” says Synlait CEO, Leon Clement.
The development will not have a material impact on Synlait’s forecast infant formula volumes.
ENDS
Greenpeace: New Anchor Butter Owner Must Go Palm Kernel-free
Science Media Centre: What To Expect From COP29 – Expert Reaction
Infrastructure New Zealand: Unlocking ‘Lazy’ Capital To Build New Infrastructure For Our Future
Parrot Analytics: Paramount Earnings - Can Ellison Strike The Right Balance?
NZ Trade and Enterprise: NZ Businesses Deliver $340 Million Trade Boost For New Zealand In China
Ngā Manu Nature Reserve: Celebrating The Return Of Tuatara To Ngāti Koata And Brook Waimārama Sanctuary
